Cathie Wood, head of Ark Investment Management, is known for making bold, conviction-driven bets, but she’s just as quick to trim positions when the strategy shifts. That pattern is playing out again this week.
ARK Investment Management has continued selling shares of Strata Critical Medical (NASDAQ: SRTA), extending a multi-day streak of consistent reductions. On April 13, the firm offloaded 182,767 shares worth about $738,378 across its ARKQ and ARKX exchange-traded funds.
This wasn’t a one-off move. The firm has been trimming SRTA daily, including a sale of 75,389 shares on April 10. That steady pattern suggests something more deliberate is happening behind the scenes.
So why is Ark pulling back from a company that’s still posting strong growth?
Ark steadily reduces Strata Critical Medical stake
Ark’s recent trade activity points to a clear trend. A systematic reduction in its exposure to Strata Critical Medical.
The April 13 sale included 144,198 shares sold through the ARK Autonomous Technology & Robotics ETF, and 38,569 shares sold through the ARK Space Exploration & Innovation ETF.
Related: Cathie Wood buys $6.9 million of surging tech stock
Notably, Ark reported no major new sales or buys in that update, making SRTA the standout move of the day.
For investors who follow Ark’s daily trades closely, this kind of repeated selling often signals a broader portfolio shift rather than short-term profit-taking.Â
Strong earnings make Ark’s decision more surprising
What makes this move stand out is that Strata Critical Medical’s fundamentals haven’t weakened. In fact, they’ve improved significantly.Â
March 03, 2026, Strata delivered a standout fourth quarter, backed by strong growth, improving margins, and raised forward guidance.
Q4 2025 highlights:
- Revenue: $66.8 million (+83.5% YoY)
- Logistics revenue: $49.2 million (+35.3% YoY)
- Clinical revenue: $17.6 million (boosted by Keystone acquisition)
- Gross profit: $14.4 million (+90% YoY)
- Gross margin: 21.6% (up from 20.8%)
- Adjusted EBITDA: $7.0 million (vs. $1.1M last year)
- Net loss: narrowed to $5.4 million (from $7.4M)
Beyond growth, profitability trends are improving, even as the company continues to invest:
- Operating cash flow: $8.3 million
- Free cash flow: $8.7 million
- Cash position: $61.2 million at year-end
Looking ahead, management is raising expectations:
- 2026 revenue guidance: $260–$275 million (raised)
- Adjusted EBITDA: $29–$33 million (raised)
- Free cash flow (ex-aircraft): $15–$22 million
Co-CEO and COO Will Heyburn pointed to continued momentum, noting the company is still exceeding its growth targets.
“We continue to demonstrate our ability to achieve and exceed the ambitious goals we set for ourselves, both for organic growth, which at 35.3% this quarter was significantly ahead of our targets, as well as for our M&A platform,” Heyburn said.
That’s what makes the move puzzling. With revenue surging, margins improving, and guidance moving higher, the business appears to be gaining strength, not losing it. So if the business is performing well, why sell?
Shutterstock
Cathie Wood appears to be reallocating toward higher-conviction bets
Ark’s strategy often involves rotating capital into its highest-conviction ideas, and recent trades suggest that’s exactly what’s happening.
Ark has been actively buying stocks tied to artificial intelligence, fintech, and genomics.
Some of the many recent purchases include:
- Palantir Technologies ( PLTR), with an $11 million buy in April
- Tesla (TSLA), with nearly $28 million added in a week
- Robinhood Markets (HOOD), one of Ark’s largest 2026 bets
- GeneDx Holdings (WGS), a consistent accumulation target
At the same time, Ark has trimmed other positions, including:
- Advanced Micro Devices (AMD) shares, worth about $10.52 million, as Yahoo Finance reports
- 33,812 shares of Teradyne (TER) worth $10.8 million as reported in Investing.com
This pattern suggests Ark is freeing up capital to double down on areas it sees as having stronger long-term upside, particularly AI-driven companies.
What this means for youÂ
Cathie Wood’s trades are often closely watched because they can signal emerging trends. Or else, shifts in market conviction.
In this case, the continued selling of Strata Critical Medical doesn’t necessarily mean the company is struggling. Instead, it likely reflects a portfolio rebalancing strategy.
Related: Cathie Wood buys $11 million of tumbling megacap tech stock